Featuring Elric Langton, Mike Caine aka PJ1 and Chis aka Toyin | 18 April 2025
I, Mike Cain, Alex Langton, and Chris have a financial interest in SkinBioTherapeutics. Mike and Alex have a financial interest in OptiBiotix Health. Elric and Mike have a financial interest in Insig AI.
In this episode, we delve into SkinBioTherapeutics’ NDA progress, its current cash position, and recent commentary from brokers. We also entertain a rather extraordinary theory—potentially mind-blowing, or, admittedly, bordering on the eccentric. Either way, it raises questions worth pondering.
We reflect on investor takeaways from the ongoing situation at Minoan, highlighting key lessons that shouldn’t be overlooked. The conversation then shifts to a recent milestone event involving Insig AI and the FCA, before concluding with a discussion on OptiBiotix, where we attempt to clarify the company’s current standing and strategic direction.
Opinions
We offer no advice or solicit the purchase of shares in any companies we discuss. However, shares go up and down in value, making your financial situation risky.
The views and opinions contained within these editorials are for research purposes and are the opinions of the author(s). We aim to be as accurate as possible, but stress that you should also perform your own research and never act solely on the contents of these editorials.
Share this post